N°25 - December 2017
Following the acquisition of Cytec at year end 2015 and in order to provide a reference frame for the Group’s performance going forward, Solvay presents pro forma information for the year 2015.
These unaudited figures represent a situation as if the acquisition had taken place on January 1, 2015.
2015 Key Data
Stock performance since January 1, 2016
Since the beginning of the year, equity markets in general have been affected by the financial markets concerns on the global economic slowdown - particularly in emerging markets – and by the geopolitical situation. Moreover, the Chemical sector widely and Solvay in particularly, have been further impacted by the fall in prices of raw materials and oil, compounded with its more cyclical nature. In this context, Solvay’s share price has gone down by 15.3% since the beginning of the year, what compares with a decline on average of 13.0% for its European peer group in the Chemical industry (i.e. Akzo Nobel, Arkema, BASF, Clariant, DSM, Evonik, Lanxess), during the same period.
source : Capital IQ as of 25th February 2016
In this environment, and assuming no further deterioration in market conditions, Solvay expects its REBITDA in 2016 to grow by high-single digits compared to the 2015 pro forma REBITDA  of €2,336 m (including Cytec).
 The current definition of REBITDA equates to Underlying EBITDA going forward.
The Solvay/Solar Impulse partnership flies on in 2016
We have also renewed our partnership with Solar Impulse for the final 2016 portion of the round-the-world flight.